Introduction
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the Western world, despite recent advances in surgery, radiotherapy and chemotherapy{(1). Tumor progression of CRCs is governed by either genetic or epigenetic changes intrinsic to Most studies revealed longer disease-free and overall survival for patients with MSI-H CRC than for patients with MSS CRC (8-12)}, even in the case of deep local invasion of the primary tumor{(13)}. These studies suggested a protective role for T lymphocytes, which clearly infiltrated more extensively in MSI-H than in MSS CRCs{(14)}. Pronounced lymphocytic infiltration of tumors has long been associated with an improved prognosis{(15), (16)}. MSI in combination with a high content of intraepithelial cytotoxic lymphocytes was related to improved overall survival in a group of exclusively right sided CRCs {(17), (18)}, suggesting that a combination of both the tumor's local lymphocytosis and MMR characterization may be useful for a more accurate prognostic assessment. Contradictory results come from mouse models of colorectal cancer, and these results are consistent with the association between either chronic inflammation{(19;20)} or an increased number of inflammatory cells in tumors{(21) and tumor progression.
To determine the putative impact of microsatellite status on the anti-tumoral immune response, we analyzed histological and molecular features of tumors in patients with sporadic CRCs. We also developed a quantitative PCR assay for 15 inflammatory and T lymphocyte markers in tumours with reference to the MMR status.
Patients and Methods

Study population
This retrospective analysis included a group of 45 patients from a consecutive cohort survey study in Henri Mondor hospital. To be eligible, patients had to have undergone surgery of primary rectal or colon tumors, for which both frozen and paraffin embedded tumoral and normal tissues were available in the tissue collection bank. None had known hereditary cancer, ulcerative colitis, or Crohn's disease. Consecutive patients were routinely informed about biological researches on tissues that did not include hereditary genetic characterization.
Their tissue materials could be used for the current study except if "formal opposition" was mentioned to doctors. Ethical committee approved the procedure.
Histology and pathology
Tissues were immediately examined after surgery, and normal and tumoral representative samples were frozen, fixed in formalin, and archived in a tissue collection bank. Diagnoses and tumor descriptions were done on H&S stained tissues according to the pTNM classification. Histopathology was further examined for lymphocyte infiltration and for a mucous component.
Analysis of MMR status by immunohistochemistry
Representative samples from adenocarcinoma and normal mucosa adjacent to the tumor were selected in each case and paraffin sections were sent to an automated immunostainer. Tissue sections were incubated in citrate buffer with the following antibodies: G168-728 Ab (recognizes hMLH1 antigen, Ab was diluted 1:40; Pharmingen, San Diego CA-USA), FE11 Ab (recognizes hMSH2 antigen, Ab diluted 1:25; Calbiochem, Cambridge, USA), 44 Ab (recognizes hMSH6, Ab diluted 1:100; Zymed Laboratories Inc, South San Francisco, CA, USA), all in a boiling water bath. An avidin-biotin complex (ABC Vectastain Kit, Vector Lab) was used to reveal the antigen. Positive controls included slides from tumors with normal expression of hMLH1, hMSH2 and hMSH6; negative controls included slides with no primary antibodies. Two observers with no prior knowledge of the PCR results assessed all cases independently, and cases with discrepancies were further evaluated until agreement was reached between the observers.
Analysis of IL-17 expression by Immunohistochemistry
Representative samples (N>5) from tumoral and autologous normal mucosa were selected for each case, and paraffin-embedded sections (4µm) were treated by boiling in citrate buffer (pH 6) in a microwave (800W, 5min X3). Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 20 min followed by a wash in PBS for 5 min. Nonspecific antibody binding sites were coated by the addition of a horse serum (1:20 in PBS, for 25 min). Serum was then removed and anti human IL17 goat antibody (R&D Systems, Lille, France) diluted in the PBS (1:40) was added to the tissue sections (room temperature for 1 h).
Immunohistochemical staining was undertaken using a Vectastain Universal Elite kit according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA, USA).
The chromagen, Sigmafast DAB (3′,3′-diaminobenzidine) (Sigma-Aldrich) was incubated with the tissue sections in the dark (room temperature for 4 min). The sections were the counterstained with haematoxylin.
For double staining IL17/CD3, the goat anti-human IL-17 antibody (diluted 1:40) was applied first and incubated for 2h hrs. Immunohistochemical staining was undertaken using a Vectastain AP kit according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA, USA) and visualization was done with Naphtol/Fast Red(Sigma-Aldrich).
Subsequently, a rabbit anti-human CD3 (diluted 1:50 in PBS, Dako, France) was incubated for 1 hr. Immunohistochemical staining was undertaken using ImmPRESS system (Vector Laboratories, Burlingame, CA, USA) and visualization was done with DAB substrate. Therefore, to normalize the we used the ratio of mRNA copy number of each marker gene / CD3.
Analysis of microsatellite stability by PCR
Non-parametric tests were used because of the non-normal distributions of mRNA levels.
Overall differences in immune marker expression between the tumoral (T) and autologous non-tumoral (NT) specimens were analyzed by using the paired non-parametric Wilcoxon signed-rank test. For significant variations, gene expression levels between tumoral and nontumoral specimens were also compared in each phenotypic subgroup (MSI-H and MSS).
Differences between MSI-H and MSS phenotypes were evaluated by comparing the T/NT ratio of mRNA expression using the two-sample Wilcoxon rank-sum test. All tests were two-
tailed. An adjustment for multiple testing was done using the Bonferroni correction, and p Perf/CD3 and GzB/CD3, were significantly higher in tumor tissues than in autologous NT specimens (Table 2) . Adjusting on MMR status, only the perforin T/NT ratio was higher in MSI-H tissues than in MSS tissues. The expression of Gz B/CD3 was significantly higher in tumor (as compared to NT) specimens only if they had an MSS phenotype. The GzA/CD3 ratio did not differ between tumoral and autologous NT specimens.
MSS phenotype and higher Foxp3 and IL-17 expressions in tumor infiltrates
Overall analysis showed that the expression ratios IL-17/CD3 and Foxp3/CD3 (Table2), and IL-8, IL-1β, IL-6, and TGF-β expression (Table 3) Results are expressed as median (first-third quartiles) of the ratio of target gene to CD3 mRNA copy numbers. * P value of the paired non-parametric comparisons between tumoral and non tumoral tissues (Wilcoxon signed-rank test). † P value of the non-parametric comparisons between MSS and MSI-H phenotypes. After using the Bonferroni correction for multiple testing, P ≤ .003 was considered statistically significant. The P values are in bold. 
